CANY
ORGO icon

Caxton Associates (New York)’s Organogenesis Holdings ORGO Stock Holding History

Caxton Associates (New York)’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,074
Closed -$88.3K – 569
2024
Q1 		$88.3K Buy
+31,074
New +$106K ﹤0.01% 441
2023
Q2 		– Sell
-12,306
Closed -$26.2K – 612
2023
Q1 		$26.2K Buy
+12,306
New +$30.4K ﹤0.01% 478
2021
Q2 		– Sell
-39,128
Closed -$713K – 570
2021
Q1 		$713K Buy
+39,128
New +$530K 0.06% 108

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caxton Associates (New York)'s ORGO Position: Q2 2024 in Review

Caxton Associates (New York) sold out of Organogenesis Holdings (ORGO) in Q2 2024, closing a stake of 31,074 shares — an estimated $88.3K sold.

Caxton Associates (New York) first reported a position in ORGO in Q1 2021 and held it in 3 quarters. The position peaked at $713K in Q1 2021. 115 funds tracked by Wall St. Rank hold ORGO as of Q2 2024.

  • Caxton Associates (New York) reported no remaining Organogenesis Holdings position as of Q2 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 31,074 Organogenesis Holdings shares in Q2 2024, an estimated $88.3K.
  • Caxton Associates (New York) first reported a position in Organogenesis Holdings in Q1 2021 and held it in 3 quarters.
  • Caxton Associates (New York)'s Organogenesis Holdings position peaked at $713K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q2 2024.

Based on Caxton Associates (New York)'s 13F filing for Q2 2024, filed 14 Aug 2024.